SEARCH

SEARCH BY CITATION

References

  • 1
    Callen JP, Bickers DR, Moy RL. Actinic keratosis. J Am Acad Dermatol 1997; 36:6503.
  • 2
    Yantsos VA, Conrad N, Zabawski E et al. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg 1999; 18:314.
  • 3
    Kocsard E. Solar keratoses and their relationship to non-melanoma skin cancers. Australas J Dermatol 1997; 38 (Suppl. 1):S30.
  • 4
    Uhoda I, Quatresooz P, Pierard-Franchimont C, Pierard GE. Nudging epidermal field cancerogenesis by imiquimod. Dermatology 2003; 206:35760.
  • 5
    Carlson JA, Scott D, Wharton J et al. Incidental histopathologic pattern: possible evidence of field cancerisation surrounding skin tumors. Am J Dermpathol 2001; 23:4947.
  • 6
    Testerman TL, Gerster JF, Imbertson LM et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995; 58:36572.
  • 7
    Imbertson LM, Beaurline JM, Couture AM et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110:7349.
  • 8
    Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50:71421.
  • 9
    Szeimies RM, Gerritsen MJ, Gupta G et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51:54755.
  • 10
    Korman N, Moy R, Ling M et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141:46773.
  • 11
    Thai K-E, Fergin P, Freeman M et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004; 43:68792.
  • 12
    Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24:9901000.
  • 13
    Gupta AK, Davey V, McPhail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005; 9:20914. Incorporating Medical and Surgical Dermatology [serial online]. 2 Mar 2006. Available from http://www.springerLink.com (accessed 3 April 2006).
  • 14
    Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134:2530.
  • 15
    Reichard O, Gunnar N, Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferon [alpha]-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351:837.
  • 16
    Duncan M, Berman B. Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation. J Exp Med 1985; 162:51627.
  • 17
    Granstein RD, Flotte TJ, Amento EP. Interferons and collagen production. J Invest Dermatol 1990; 95 (6 Suppl.):75S80S.
  • 18
    Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol 2001; 69:51321.
  • 19
    Tucci M, Offidani A, Lucarini G et al. Advances in the understanding of malignant transformation of keratinocytes: an immunohistochemical study. J Eur Acad Dermatol Venereol 1998; 10:11824.